32 days to first decision for reviewed manuscripts only
21 days to first decision for all manuscripts
59 days from submission to acceptance
12 days from acceptance to publication
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
Anemia is considered a negative prognostic risk factor for survival in patients with myelofibrosis. Most patients with myelofibrosis are anemic, and 35–54 % present with anemia at diagnosis. Ruxolitinib, a pot...
Citation: Experimental Hematology & Oncology 2015 4:26